Insider Transactions in Q2 2021 at Neogenomics Inc (NEO)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2021
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
56
-3.03%
|
$2,408
$43.99 P/Share
|
|
Jun 18
2021
|
Clive Morris President of Inivata |
BUY
Grant, award, or other acquisition
|
Direct |
10,708
+50.0%
|
-
|
|
Jun 11
2021
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,389
+3.82%
|
$12,501
$9.11 P/Share
|
|
Jun 08
2021
|
Bruce K Crowther Director |
SELL
Open market or private sale
|
Direct |
20,734
-29.49%
|
$850,094
$41.46 P/Share
|
|
Jun 08
2021
|
Bruce K Crowther Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,734
+7.41%
|
$352,478
$17.48 P/Share
|
|
Jun 03
2021
|
George Cardoza President & COO, Lab Ops |
SELL
Open market or private sale
|
Direct |
31,107
-14.96%
|
$1,244,280
$40.11 P/Share
|
|
Jun 02
2021
|
George Cardoza President & COO, Lab Ops |
SELL
Open market or private sale
|
Direct |
169,230
-44.88%
|
$6,769,200
$40.39 P/Share
|
|
Jun 02
2021
|
Stephen M Kanovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+25.09%
|
-
|
|
Jun 02
2021
|
Bruce K Crowther Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+5.85%
|
-
|
|
Jun 02
2021
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+8.41%
|
-
|
|
Jun 02
2021
|
Rachel A Stahler Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+34.77%
|
-
|
|
Jun 02
2021
|
Kevin C Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+8.29%
|
-
|
|
Jun 02
2021
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+38.78%
|
-
|
|
Jun 02
2021
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+3.24%
|
-
|
|
May 25
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Open market or private sale
|
Direct |
130,604
-46.53%
|
$5,093,556
$39.31 P/Share
|
|
May 25
2021
|
Robert J. Shovlin President, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
126,958
+12.82%
|
$2,285,244
$18.65 P/Share
|
|
Apr 22
2021
|
Lawrence Martin Weiss Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,050
+6.4%
|
$475,950
$19.05 P/Share
|
|
Apr 19
2021
|
Mark Mallon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,736
+50.0%
|
-
|